董事Luke Evnin报告在三天内出售了 Werewolf Therapeutics, Inc. (NASDAQ:HOWL) 的普通股，交易总额约为61,787美元。这些交易发生在2026年1月13日至1月15日期间，价格范围在0.55美元至0.57美元之间。根据 InvestingPro 数据，这家市值仅为2718万美元的微型生物技术公司在过去一年中股价下跌了超过60%。

The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a decrease of 10.86% from the prior estimate of $5.95 dated December 18, 2025.

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock over three days, with the transactions totaling approximately $61,787. The sales occurred between ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL), a micro-cap biotech company valued at just $31.07 million, in three separate transactions, with the total value ...